Literature DB >> 34280058

A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness.

Karolina Kozak1,2, Philip H Smith3, Darby J E Lowe1,2, Andrea H Weinberger4, Ziva D Cooper5,6,7, Rachel A Rabin8, Tony P George1,2,9.   

Abstract

BACKGROUND: While males are more likely diagnosed with cannabis use disorder (CUD), females are more susceptible to developing and maintaining CUD. Yet, for both sexes, CUD is associated with high rates of comorbid mental illness (MI).
OBJECTIVES: To identify and compare sex differences in the prevalence of comorbid CUD amongst individuals with/without MIs.
METHODS: This systematic review generated pooled odds ratios (OR) and 95% confidence intervals (CI) from 37 studies (including clinical trials, cohort, and case-control studies) among individuals with and without MIs, quantifying sex differences in rates of comorbid CUD. A meta-analysis was also completed.
RESULTS: In the CUD-only group, males were twice as likely to have CUD than females (OR = 2.0, CI = 1.9-2.1). Among MIs, males were more likely than females to have CUD comorbid with schizophrenia (OR ~2.6, CI = 2.5-2.7) and other psychotic, mood, and substance use disorders (1> OR <2.2, CI = 0.7-2.6). The reverse association (females > males) was observed for anxiety disorders and antisocial personality disorder (OR = 0.8, CI = 0.7-1.0). Among females, MIs increased the likelihood of having CUD, except for psychotic disorders and depression. A meta-analysis was inconclusive due to high heterogeneity across studies. Thus, comparisons across MI groups were not possible.
CONCLUSION: While males are more likely to be diagnosed with CUD, there are important sex differences in the prevalence of CUD across MI diagnoses that should be taken into account when approaching CUD prevention and determining treatment efficacy.

Entities:  

Keywords:  Cannabis; bipolar disorder; cannabis use disorder; comorbidity; depression; mental illness; meta-analysis; schizophrenia; sex differences

Mesh:

Year:  2021        PMID: 34280058      PMCID: PMC9144491          DOI: 10.1080/00952990.2021.1946071

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.912


  41 in total

1.  Cannabis use and the course and outcome of major depressive disorder: A population based longitudinal study.

Authors:  Daniel Feingold; Jürgen Rehm; Shaul Lev-Ran
Journal:  Psychiatry Res       Date:  2017-02-12       Impact factor: 3.222

2.  Age of initiation and substance use progression: A multivariate latent growth analysis.

Authors:  Leah S Richmond-Rakerd; Wendy S Slutske; Phillip K Wood
Journal:  Psychol Addict Behav       Date:  2017-08-14

3.  Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia.

Authors:  Harry Man Xiong Lai; Thiagarajan Sitharthan
Journal:  Am J Drug Alcohol Abuse       Date:  2012-07-02       Impact factor: 3.829

4.  Types of marijuana users by longitudinal course.

Authors:  D B Kandel; K Chen
Journal:  J Stud Alcohol       Date:  2000-05

Review 5.  Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective.

Authors:  Ziva D Cooper; Rebecca M Craft
Journal:  Neuropsychopharmacology       Date:  2017-07-17       Impact factor: 7.853

6.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 7.  Cannabinoid receptors: where they are and what they do.

Authors:  K Mackie
Journal:  J Neuroendocrinol       Date:  2008-05       Impact factor: 3.627

Review 8.  Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia.

Authors:  Kirsten R Müller-Vahl; Hinderk M Emrich
Journal:  Expert Rev Neurother       Date:  2008-07       Impact factor: 4.618

Review 9.  Cannabinoid-hormone interactions in the regulation of motivational processes.

Authors:  Hassan H López
Journal:  Horm Behav       Date:  2009-10-09       Impact factor: 3.587

Review 10.  The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study.

Authors:  Louisa Degenhardt; Alize J Ferrari; Bianca Calabria; Wayne D Hall; Rosana E Norman; John McGrath; Abraham D Flaxman; Rebecca E Engell; Greg D Freedman; Harvey A Whiteford; Theo Vos
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

View more
  1 in total

1.  Differences in alcohol and cannabis use amongst substance use disorder patients with and without comorbid attention-deficit/hyperactivity disorder.

Authors:  Corné Coetzee; Ilse Truter; Anneke Meyer
Journal:  S Afr J Psychiatr       Date:  2022-04-14       Impact factor: 1.242

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.